Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease

NCT02194985 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT02194985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02194985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Lead sponsor
Amicus Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 14, 2015
Completion date
October 23, 2019
Enrollment
84 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease